US 12,247,080 B2
Anti-DR5 antibodies and methods of use thereof
Marije Overdijk, Utrecht (NL); Kristin Strumane, Werkhoven (NL); Rik Rademaker, Copenhagen (DK); Esther Breij, Utrecht (NL); Janine Schuurman, Diemen (NL); and Paul Parren, Odijk (NL)
Assigned to GENMAB B.V., Utrecht (NL)
Filed by GENMAB B.V., Utrecht (NL)
Filed on Dec. 1, 2020, as Appl. No. 17/108,373.
Application 17/108,373 is a division of application No. 16/451,714, filed on Jun. 25, 2019, granted, now 10,882,913.
Application 16/451,714 is a continuation of application No. 15/780,268, abandoned, previously published as PCT/EP2016/079518, filed on Dec. 1, 2016.
Claims priority of application No. PA 2015 00771 (DK), filed on Dec. 1, 2015; application No. PA 2015 00787 (DK), filed on Dec. 7, 2015; application No. PA 2015 00788 (DK), filed on Dec. 7, 2015; application No. PA 2016 00701 (DK), filed on Nov. 10, 2016; and application No. PA 2016 00702 (DK), filed on Nov. 10, 2016.
Prior Publication US 2021/0324096 A1, Oct. 21, 2021
Int. Cl. A61K 39/395 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01); C07K 16/30 (2006.01); C12N 15/62 (2006.01); A61K 38/00 (2006.01); A61K 39/00 (2006.01); C07K 14/715 (2006.01); C07K 16/46 (2006.01)
CPC C07K 16/2878 (2013.01) [A61P 35/00 (2018.01); C07K 16/30 (2013.01); C12N 15/62 (2013.01); A61K 38/00 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 16/46 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/52 (2013.01); C07K 2317/526 (2013.01); C07K 2317/73 (2013.01); C07K 2317/75 (2013.01)] 15 Claims
OG exemplary drawing
 
1. A method of treating a DR5-expressing solid tumor and/or hematological tumor comprising administering to a subject in need thereof an effective amount of a composition comprising a carrier, and a first antibody and a second antibody which bind to human DR5, wherein
(a) the first antibody comprises a variable heavy chain (VH) region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 1, 8, and 3, respectively, and a variable light chain (VL) region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 5, the sequence FAS, SEQ ID NO: 6, respectively, and
(b) the second antibody comprises a VH region comprising VHCDR1, VHCDR2, and VHCDR3 domains comprising the amino acid sequences set forth in SEQ ID NOs: 10, 2, and 11, respectively, and a VL region comprising VLCDR1, VLCDR2, and VLCDR3 domains comprising the amino acid sequences set forth in SEQ ID NO: 13, the sequence RTS, SEQ ID NO: 14, respectively, and
wherein both the first antibody and second antibody comprise a Fc region of a human immunoglobulin IgG, and wherein the Fc region of both the first antibody and the second antibody comprises a substitution of an amino acid position corresponding to E430, E345 or S440 in human IgG1, wherein the numbering is according to the EU Index.